^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pasritamig (JNJ-8343)

    i
    Other names: JNJ-8343, JNJ-78278343, JNJ78278343, JNJ8343, JNJ 78278343, JNJ 8343
    Associations

    News

    Trials
    Company:
    J&J, Zymeworks
    Drug class:
    CD3 agonist, KLK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=144, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Jan 2027 | Trial primary completion date: Oct 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    3d
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> Mar 2027 | Trial primary completion date: Sep 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    3d
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=277, Recruiting, Janssen Research & Development, LLC | N=185 --> 277
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • pasritamig (JNJ-8343)
    16d
    Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) (ChiCTR2600117391)
    P3, N=800, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P3 trial
    |
    docetaxel • pasritamig (JNJ-8343)
    16d
    A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ- 78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer (ChiCTR2600117636)
    P3, N=663, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P3 trial
    |
    pasritamig (JNJ-8343)
    1m
    A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Janssen Research & Development, LLC
    New P1 trial
    |
    AR (Androgen receptor)
    |
    pasritamig (JNJ-8343)
    2ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=144, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    2ms
    KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=800, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • prednisone • pasritamig (JNJ-8343)
    2ms
    KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=800, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2029
    Trial completion date
    |
    docetaxel • prednisone • pasritamig (JNJ-8343)
    3ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=177, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2028 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    3ms
    KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=800, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    docetaxel • prednisone • pasritamig (JNJ-8343)
    4ms
    A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=216, Recruiting, Janssen Research & Development, LLC | Active, not recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date
    |
    pasritamig (JNJ-8343)